Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

10 Stocks to Buy if You Want to Support Companies Taking Covid-19 Seriously  

By Will Ashworth, InvestorPlace Contributor

A recent survey suggests a majority of U.S. companies could mandate vaccines. Here are 10 stocks to buy taking Covid-19 seriously.

Alibaba Stock Is Tough To Recommend Owning Right Now

By Will Ashworth, InvestorPlace Contributor

A recent rape accusation at Alibaba has me wondering if I can continue to support investors owning BABA stock. Here’s why I feel this way.  

Nano Dimension Stock Is a Good Long-Term Buy Here, But Patience Is Key

By Will Ashworth, InvestorPlace Contributor

While there is a safer way to play Nano Dimension and NNDM stock, the CEO’s Q2 2021 message to shareholders might suggest otherwise.

Will Support.com’s Hail Mary Hit the Target?

By Will Ashworth, InvestorPlace Contributor

Support.com’s merger vote is on Sep. 10. While SPRT stock is up more than 1,200% over the past year, one plus one does not equal three.   

Zomedica Continues to Execute Poorly

By Will Ashworth, InvestorPlace Contributor

It's been 3.5 months since Zomedica launched Truforma. Unfortunately, due to its poor execution, ZOM stock continues to suffer.

Load More